On November 4, 2024, Carol Lindstrom, Director at Exponent Inc (EXPO, Financial), executed a sale of 1,039 shares of the company. The transaction was filed on the same day through an SEC Filing. Following this transaction, the insider now owns 5,871 shares of Exponent Inc.
Exponent Inc is a science and engineering consulting firm known for its work in analyzing accidents and failures, and testing products and materials. The company's expertise is often sought in litigation, where its findings and testimonies can provide critical evidence.
Over the past year, Carol Lindstrom has sold a total of 1,971 shares and has not purchased any shares. This recent sale is part of a broader trend at Exponent Inc, where there have been 22 insider sells and no insider buys over the past year.
Shares of Exponent Inc were priced at $96.32 on the day of the sale, positioning the company with a market cap of approximately $4.99 billion. The price-earnings ratio of the company stands at 47.44, significantly above both the industry median of 15.69 and the historical median for the company.
The stock's valuation according to GF Value is $101.95, suggesting that at a price of $96.32, Exponent Inc is Fairly Valued. The GF Value is calculated considering historical trading multiples, an adjustment factor based on past performance, and future business expectations.
This insider sell event might interest investors tracking insider behaviors as an indicator of confidence levels concerning the company's future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
